The effect of this peptide was even seen in combination treatment with cisplatin, suggesting an in vivo sensitization of ovarian cancer cells to cisplatin by inhibiting BRCA1- IRIS survival pathways (Figure 1) [3]. Here, BRCA1 is linked to ovarian cancer.